Brainwave-Discovery Ltd in collaboration with the NC3Rs UK launches a solution as part of the National CRACK IT initiative which is desgined to introduce exciting new technologies that replace, reduce and/or refine the use of animals in research and development. Brainwave-Discovery has proposed a next generation series of neurodegenerative models and is seeking development partners in the pharmaceutical industry..

Matt B Mahoney joins Brainwave as Director of Business Development - North American Region. Matt B. Mahoney has been working closely with Drosophila for over ten years. After studying genetics at the University of California, Berkeley, Matt joined the Alzheimer's disease team at Exelixis Inc., where he ran forward genetic screens for various clients. Subsequently, he was recruited to EnVivo Pharmaceuticals, where he helped to optimize and run their Drosophila behavioral screening platform and was integral to the identification of multiple treatment candidates for neurodegenerative diseases. This group spun off into a separate company, Vitruvean, LLC, where Matt was responsible for Drosophila-based drug screening, marketing and business development. This invaluable experience is now focused on the development of Brainwave-Discovery's business in the USA and Canada. Customers in this region should contact Matt directly on m.mahoney@brainwave-discovery.com

The scanning electron micrograph image of a Drosophila head kindly produced for Brainwave by A. J Dornan from the Institute of Molecular, Cell and Systems Biology, Glasgow University and used in many of our presentations was selected for incorporation in this year's Nexxus calendar.

Wayne Davies, BWD CEO visits Tokyo (25/26th Ovt) and Osaka (28/29th October) as part of the UKTI Biopharma mission to Japan. To arrange a meeting, please contact w.davies@brainwave-discovery.com

Brainwave-Discovery Ltd announces that it has started work on developing 40 humanised models for synaptic disorders. The first 10 genes are being selected on the basis of roles in cognition and its disorders and will allow comparison with existing rodent models. As the programme progresses the emphasis will move towards entirely novel proteins that are canditates for the next generation of therapies. BWD has appointed staff scientist Lysimachos Zografos to lead this new development.

Synsys: A European expertise Network on building the synapse. SynSys scientists have attracted signiticant fuding from the EU to do novel research on the synapse. Only by bringing together a large European group of specialists, each having their own expertise in synapse experiments and computation SynSys can achieve a new level of understanding of the synapse. Branwave-Discovery is one of the SME partners and will develop humanised fly models for synaptic proteins.

Wayne Davies, BWD CEO visits companies in the Boston area and attends the Neurodegeneration forum in Cambridge Mass.

Brainwave-Discovery Ltd engage with UKTI to make initial contacts into the east coast US pharamaceutical and biotechnology markets with first contacts in the Boston, New Jersey and New York areas.

Brainwave-Discovery Ltd is reviewed by Scottish Enterprise and rated as having high growth potential. Sarah Kenhard is appointed as our account manager.

Brainwave-Discovery Ltd presents at EPIS 2009